PCMP-E58 Antibody
Description
Overview of E58 Antibody
E58 is a mouse monoclonal antibody (mAb) that binds to group 1 allergens from cedar pollens (e.g., Jun a 1, Cup s 1, Cry j 1) found in central U.S.A., France, and Japan . Its primary function is to inhibit IgE binding to these allergens, reducing allergic responses .
Epitope Mapping
E58 binds to surface-exposed regions of group 1 allergens. Sequence alignment and structural modeling revealed:
-
Epitope variability: Differences in inhibitory activity across allergens (Jun a 1 > Cup s 1 > Cry j 1) .
-
Predicted binding sites: Analyzed using the IEDB database, highlighting conformational epitopes critical for IgE interference .
Recombinant Constructs
-
scFv E58: A single-chain variable fragment (V<sub>H</sub> + V<sub>L</sub> + C<sub>κ</sub>) expressed in E. coli for functional studies .
-
pFab E58: A four-domain Fab fragment (V<sub>H</sub> + V<sub>L</sub> + C<sub>κ</sub> + C<sub>H1</sub>) used in surface plasmon resonance assays .
In Vitro Efficacy
| Assay Type | Target Allergen | IgE Inhibition (%) | Citation |
|---|---|---|---|
| ELISA Inhibition | Jun a 1 | 65–85 | |
| Cup s 1 | 40–60 | ||
| Cry j 1 | 30–50 |
Comparative Analysis
E58 outperformed other IgE-modulating antibodies (e.g., Bet v 1-targeting mAbs) by:
-
Consistency: Uniform reduction of IgE binding across patient sera .
-
Broad-spectrum activity: Effective against multiple cedar pollen allergens .
Proposed Applications
-
Nasal spray formulation: Prophylactic use during pollen seasons to reduce allergic rhinitis symptoms .
-
Prevention of sensitization: Early intervention to block IgE-mediated immune priming .
Advantages Over Alternatives
| Feature | E58 mAb | Conventional Therapies |
|---|---|---|
| Specificity | Targets multiple allergens | Limited to single allergens |
| Mechanism | Structural disruption of IgE epitopes | Symptom suppression (antihistamines) |
| Durability | Long-term prophylaxis | Short-term relief |
Research Milestones
-
Patent: U.S. Patent 8,883,154B2 (issued 2014) covers E58’s therapeutic use .
-
Funding: Supported by NIAID and American Lung Association grants .
Limitations and Future Directions
Product Specs
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
